Annual Report 2024

NOTESTOTHE CONSOLIDATED FINANCIAL STATEMENTS For the year ended 31 December 2024 125 The United Laboratories International Holdings Limited Annual Report 2024 35. CAPITAL COMMITMENTS 2024 2023 RMB’000 RMB’000 Capital expenditure in respect of the acquisition of property, plant and equipment contracted for but not provided in the consolidated financial statements 2,147,126 989,055 36. DERIVATIVE FINANCIAL INSTRUMENTS 2024 2023 RMB’000 RMB’000 Foreign currency forward contracts – current liabilities – (25,587) Foreign currency forward contracts – non-current liabilities – (19,191) – (44,778) Major terms of the foreign currency forward contracts are as follows: 31 December 2024 No currency forward contracts hedged by the Group. 31 December 2023 Major terms of the foreign currency forward contracts are as follows: Total notional amount Final Maturity Exchange rate Sell USD 140,000,000 30 October 2025 USD1: RMB7.025 Sell USD 66,000,000 29 October 2025 USD1: RMB6.960 Sell USD 44,000,000 29 October 2025 USD1: RMB6.960 The forward contracts represent the multiple currency forward transactions to be settled on multiple settlement dates on a monthly basis, until the final maturity date, or the date of reaching the exchange rate capped in the respective forward contracts. During the year ended 31 December 2024, all forward contracts were settled as the respective capped exchange rates have been reached.